Dr. Lipchik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Froedtert & Med College of Wisconsin
8701 West Watertown Plank Road
Milwaukee, WI 53226Phone+1 414-955-7040Fax+1 414-955-0175
Summary
- Randolph Lipchik, MD, is a pulmonologist located in Milwaukee, WI, specializing in interstitial lung diseases. He completed his education in Internal Medicine at McGill University and his fellowship in Pulmonary Disease and Critical Care Medicine at the University of Michigan. He is currently a Professor of Medicine at the Medical College of Wisconsin. Dr. Lipchik has published extensively, with several of his studies focused on idiopathic pulmonary fibrosis and respiratory therapy. He has been involved in clinical trials assessing treatments for idiopathic pulmonary fibrosis. His accolades include receiving the CMS Meaningful Use Stage 1 Certification and being recognized as a Super Doctor and Top MD.
Education & Training
University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1990
McGill University Faculty Medicine HospitalInternal Medicine, 1984 - 1987
McGill University Faculty of MedicineClass of 1984
Certifications & Licensure
WI State Medical License 1990 - 2025
MI State Medical License 1987 - 1992- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2019 Feb 19
Publications & Presentations
PubMed
- 3 citationsOptimizing Respiratory Therapy Resources by De-Implementing Low-Value Care.Kellianne Fleming, Jessica L George, Sarah J Bazelak, Julie A Roeske, Adam D Biggs
Respiratory Care. 2023-05-01 - 5 citationsA 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.Jerome O. Cantor, Shuren Ma, Xingjian Liu, Michael Campos, C Strange
Respiratory Medicine. 2021-06-01 - 11 citationsHospitalizations in patients with idiopathic pulmonary fibrosis.Hyun J Kim, Laurie D. Snyder, Ayodeji Adegunsoye, Megan L. Neely, Shaun Bender
Respiratory Research. 2021-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
